Catherine Bollard, Senior Vice President and Chief Research Officer at Children’s National Hospital, shared a post on LinkedIn:
“Children with high-risk brain tumors urgently need new treatment options.
One of the biggest challenges we face is tumor complexity – these cancers are made up of different cell types that can adapt and evade therapies targeting a single marker.
In our latest manuscript (supported by generous funders reflecting the strength of the community in fighting these deadly cancers, including: the Chance for Life Foundation: anonymous private investors supporting the Children’s National Hospital ’s Brain Tumor Institute: Cancer Research UK Science and Innovation, the National Cancer Institute (NCI) and The Mark Foundation for Cancer Research , through the Cancer Grand Challenges), published today in Nature Medicine, we share early findings from the ReMIND trial. We’ve been exploring a personalised T-cell therapy approach, using each patient’s own immune cells and training them to recognise multiple tumor markers at once.
Our early results show that this type of therapy is feasible, can be tracked in the body, and is generally well tolerated.
There’s still more to learn about whether this approach can improve outcomes – but this is an important step towards treatments that better reflect the complexity of these tumors.
Huge congratulations to Gene Hwang (Principal Investigator of the REMIND trial), co-first authors Stephanie Gomez and Rachel DiCioccio along with co-authors including Patrick Hanley, Chase D. McCann, Fahmida Hoq, Roger Packer, Holly Meany ,Anqing Zhang , Brian Rood, Lindsay Kilburn , Emily Reynolds , Jenn Webb, C. Russell Y. Cruz , Adriana Fonseca Sheridan , Jay Tanna, Anushree Datar – it takes a village!”
Other articles featuring Catherine Bollard on OncoDaily.